Page last updated: 2024-10-30

edaravone and Cytokine Release Syndrome

edaravone has been researched along with Cytokine Release Syndrome in 1 studies

Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.

Research Excerpts

ExcerptRelevanceReference
"Cytokine storm is the most prominent hallmark in patients with coronavirus disease 2019 (COVID-19) that stimulates the free radical storm, both of which induce an overactive immune response during viral infection."3.11Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial. ( Ardalan, M; Haramshahi, M; Hejazian, SM; Javanali, F; Mirghaffari, A; Moslemi, M; Sadeghi, A; Shaddelan, M; Sharifi, A; Valizadeh, H; Zununi Vahed, S, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Moslemi, M1
Hejazian, SM1
Shaddelan, M1
Javanali, F1
Mirghaffari, A1
Sadeghi, A1
Valizadeh, H1
Sharifi, A1
Haramshahi, M1
Ardalan, M1
Zununi Vahed, S1

Trials

1 trial available for edaravone and Cytokine Release Syndrome

ArticleYear
Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial.
    Inflammopharmacology, 2022, Volume: 30, Issue:4

    Topics: COVID-19 Drug Treatment; Cytokine Release Syndrome; Edaravone; Humans; Intensive Care Units; SARS-Co

2022